Intravitreal @entity1456 in the management of XXXX .

@entity1 @entity2994 @entity1456 @entity865
PURPOSE: To evaluate the role of intravitreal @entity1456 (tPA) in the management of @entity2994 ( @entity2994 ) in @entity1 with symptoms for <3 days. METHODS: We evaluated the visual outcome of a consecutive series of @entity1 with @entity2994 following intravitreal tPA injection. All @entity1 presented with visual acuity worse than 20/50 within 3 days from the onset of symptoms. Main outcome measures included percentage of @entity1 whose final vision improved to 20/50 or better and change in percentage of @entity1 with vision of 20/200 or worse before and after treatment. RESULTS: Twelve @entity1 received intravitreal tPA for @entity2994 . Nine @entity1 (75%) had best-corrected visual acuity of 20/200 or worse at presentation compared with 4 @entity1 (33%) at the last follow-up after treatment. Five (55%) of these 9 @entity1 had final visual acuity that improved to 20/50 or better. The remaining four @entity1 did not have improvement or their vision continued to worsen. All 4 @entity1 had fluorescein angiographic evidence of >10 disk areas of capillary nonperfusion at presentation. Overall, 8 (67%) of 12 @entity1 had final visual acuity of 20/50 or better. No side effects related to @entity865 injection were observed. CONCLUSION: Our data suggest that intravitreal tPA injection may have a beneficial role in the management of @entity2994 when used within a few days of the onset of symptoms in @entity1 with no angiographic evidence of severe capillary nonperfusion even if initial visual acuity is 20/200 or worse.
